It has come to our attention that we inadvertently mislabeled Figure 2 and Figure S3 during the final preparation of this manuscript. In Figure 2 , the number of patients in the PD (PD = progressive disease) group should have been N=5, rather than N=4. In the key on Figure S3 , the labels for the solid line and the dashed line were reversed. The solid line should be labeled ''all median,'' and the dashed line should be labeled ''tumor median.'' We also omitted to state in the legend of Figure S3 that the all median and tumor median for the CR/PR (CR = complete response; PR = partial response) group were the same. Therefore, the dotted line and the solid line for the CR/PR group in Figure S3A were overlapping. These errors have been corrected online, and we apologize for any confusion they may have caused.
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